clinically

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…

3 days ago

Angelalign Technology Denies Patent Infringement and Vows Vigorous Defense

SAN CLEMENTE, Calif., Aug. 20, 2025 /PRNewswire/ -- Angelalign Technology Inc. (6699.HK) ("Angel") categorically denies accusations of patent infringement by Align Technology Inc.…

2 weeks ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

2 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

2 months ago

EyeCare Partners Releases Inaugural Quality and Outcomes Report, Showcasing Impact and Industry-Leading Benchmarks

ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, released its first Quality and Outcomes…

3 months ago